Home » Health and medicine » COVID-19 » Licensing of patient-derived COVID-19 neutralizing antibodies to Hisun Pharma for co-development and clinical use.

Licensing of patient-derived COVID-19 neutralizing antibodies to Hisun Pharma for co-development and clinical use.

The successful collaboration between Fudan University, its affiliated Public Health Clinical Center and Active Motif has reached a new milestone. Active Motif, on behalf of the collaboration, has licensed four individual antibodies to Hisun BioRay, a leading commercial-stage biopharmaceutical company in China.

The goal of the collaboration is to have a group of recombinant GMP produced antibodies that will allow some relief to COV-19 patients with passive immunity. Passive immunity is a short-term immunity that results from the introduction of these antibodies into a person.

“I would like to congratulate Dr. Fei Lan, professor at Fudan University and Scientific Advisor of Active Motif Shanghai, Dr. Jianqing Xu, professor at Fudan affiliated Shanghai Public Health Center, as well as Dr. Haibin Wang, Senior Vice President, Zhejiang Hisun Pharmaceuticals and CEO of Hisun BioRay, the biologic division, for making this very exciting achievement a reality”, said Joe Fernandez, Chairman of Active Motif.

The goal of the collaboration is to have GMP production and Primate data available in the next two months.

“If our in vitro and viral data correlate positively in primates, these human antibodies will have the potential to do a lot of good for the treatment of COVID-19 infection and providing a lot of relief to patients. We will work together in the next few months to determine the efficacy of these antibodies in various populations. It’s an honor to Work with Dr. Wang and her staff at Hisun BioRay, says Professor Lan.

About Hisun Bioray

Hisun BioRay has end-to-end operational capabilities across the pharmaceutical value chain and currently employs more than 800 staff with offices in Taizhou, Hangzhou, and Shanghai.

About Active Motif

Active Motif, Inc. is dedicated to developing, manufacturing and delivering epigenetics-based research tools to analyze nuclear function. Its customers include life scientists from academic and government institutions, biotechnology and pharmaceutical companies, hospitals, and reference laboratories. Active Motif operates globally through its corporate headquarters in Carlsbad, California, and offices in Shanghai China, Tokyo Japan, and La Hulpe Belgium. Active Motif applies a multi-disciplinary approach to create new and modifies existing technologies to meet the current and future needs of life science researchers.

Source: https://www.activemotif.com/hisun-covid-pr


Press Release

Click here to join our weekly newsletter. We want to hear what you think about this article. Got a tip for our news team? Write to editorial@synbiobeta.com.

Editor’s picks